CN113614101B - 淀粉样肽的变体 - Google Patents

淀粉样肽的变体 Download PDF

Info

Publication number
CN113614101B
CN113614101B CN202080015845.1A CN202080015845A CN113614101B CN 113614101 B CN113614101 B CN 113614101B CN 202080015845 A CN202080015845 A CN 202080015845A CN 113614101 B CN113614101 B CN 113614101B
Authority
CN
China
Prior art keywords
iapp
asn
hiapp
leu
artificial sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080015845.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113614101A (zh
Inventor
D·莫菲特
L·诺盖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mount St Mary University
LOYOLA MARYMOUNT UNIVERSITY
Original Assignee
Mount St Mary University
LOYOLA MARYMOUNT UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount St Mary University, LOYOLA MARYMOUNT UNIVERSITY filed Critical Mount St Mary University
Priority to CN202410844356.7A priority Critical patent/CN118955675A/zh
Publication of CN113614101A publication Critical patent/CN113614101A/zh
Application granted granted Critical
Publication of CN113614101B publication Critical patent/CN113614101B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202080015845.1A 2019-02-22 2020-02-24 淀粉样肽的变体 Active CN113614101B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410844356.7A CN118955675A (zh) 2019-02-22 2020-02-24 Iapp肽、包含其的药物组合物及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809167P 2019-02-22 2019-02-22
US62/809,167 2019-02-22
PCT/US2020/019557 WO2020172686A1 (en) 2019-02-22 2020-02-24 Amyloid peptide variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410844356.7A Division CN118955675A (zh) 2019-02-22 2020-02-24 Iapp肽、包含其的药物组合物及其应用

Publications (2)

Publication Number Publication Date
CN113614101A CN113614101A (zh) 2021-11-05
CN113614101B true CN113614101B (zh) 2024-07-16

Family

ID=72145021

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080015845.1A Active CN113614101B (zh) 2019-02-22 2020-02-24 淀粉样肽的变体
CN202410844356.7A Pending CN118955675A (zh) 2019-02-22 2020-02-24 Iapp肽、包含其的药物组合物及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410844356.7A Pending CN118955675A (zh) 2019-02-22 2020-02-24 Iapp肽、包含其的药物组合物及其应用

Country Status (6)

Country Link
US (2) US12522635B2 (cg-RX-API-DMAC7.html)
EP (1) EP3927725A4 (cg-RX-API-DMAC7.html)
JP (3) JP7505713B2 (cg-RX-API-DMAC7.html)
CN (2) CN113614101B (cg-RX-API-DMAC7.html)
IL (1) IL285699A (cg-RX-API-DMAC7.html)
WO (1) WO2020172686A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4136446B1 (en) * 2020-05-19 2025-05-14 EMPA Eidgenössische Materialprüfungs- und Forschungsanstalt Method for detecting amyloid aggregates in blood

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110402308A (zh) * 2016-11-09 2019-11-01 可口可乐公司 生物基meg和聚酯纤维组合物以及其制造方法
CN112225808A (zh) * 2012-09-12 2021-01-15 生物控股有限公司 人胰岛淀粉样多肽(hiapp)特异性抗体及其用途
CN112672755A (zh) * 2018-06-15 2021-04-16 普罗克拉拉生物科学股份有限公司 通用淀粉样蛋白相互作用基序(gaim)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5814600A (en) 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
KR100994748B1 (ko) 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
JP2007527365A (ja) 2003-03-18 2007-09-27 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ アミリン凝集阻害剤およびその使用
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
GB0501348D0 (en) 2005-01-24 2005-03-02 Zyentia Ltd Compositions and methods
WO2007114838A1 (en) * 2006-03-31 2007-10-11 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
US20130022620A1 (en) 2011-06-09 2013-01-24 Ann Marie Schmidt Assays and methods pertaining to pre-amyloid intermediates
EP2718315B1 (en) 2011-06-10 2017-12-27 Novo Nordisk A/S Pramlintide derivatives
WO2015062803A1 (en) 2013-10-29 2015-05-07 Kapurniotu Aphrodite Modified segments of islet amyloid polypeptide
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112225808A (zh) * 2012-09-12 2021-01-15 生物控股有限公司 人胰岛淀粉样多肽(hiapp)特异性抗体及其用途
CN110402308A (zh) * 2016-11-09 2019-11-01 可口可乐公司 生物基meg和聚酯纤维组合物以及其制造方法
CN112672755A (zh) * 2018-06-15 2021-04-16 普罗克拉拉生物科学股份有限公司 通用淀粉样蛋白相互作用基序(gaim)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Neşe Kurt等.The Burial of Solvent-Accessible Surface Area Is a Predictor of Polypeptide Folding and Misfolding as a Function of Chain Elongation.《Journal of the American chemical society》.2005,第127卷(第45期),第15690-15691页. *
Pollen,A.等.IAPP isoform 5, partial [Pan troglodytes].《Genbank database》.2018,Accession NO. PNI98857.1. *
Selection for Nonamyloidogenic Mutants of Islet Amyloid Polypeptide (IAPP) Identifies an Extended Region for Amyloidogenicity;Ayano Fox等;《Biochemistry》;第49卷(第36期);第7783–7789页 *
The Burial of Solvent-Accessible Surface Area Is a Predictor of Polypeptide Folding and Misfolding as a Function of Chain Elongation;Neşe Kurt等;《Journal of the American chemical society》;第127卷(第45期);第15690-15691页 *

Also Published As

Publication number Publication date
US20260109744A1 (en) 2026-04-23
JP2022521266A (ja) 2022-04-06
JP2026094195A (ja) 2026-06-09
CN113614101A (zh) 2021-11-05
EP3927725A1 (en) 2021-12-29
JP7505713B2 (ja) 2024-06-25
IL285699A (en) 2021-10-31
JP7825238B2 (ja) 2026-03-06
US20220119468A1 (en) 2022-04-21
WO2020172686A9 (en) 2020-11-12
CN118955675A (zh) 2024-11-15
EP3927725A4 (en) 2023-06-14
WO2020172686A1 (en) 2020-08-27
US12522635B2 (en) 2026-01-13
JP2024125307A (ja) 2024-09-18

Similar Documents

Publication Publication Date Title
EP4004022B1 (en) Substances and methods for the treatment of Friedreich's disease
EP4431522A1 (en) Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
JP2025090703A (ja) 糖尿病の処置のためのペプチド
CN107405382A (zh) 用于改善认知的方法和组合物
US20260109744A1 (en) Amyloid peptide variants
KR20200003889A (ko) C-말단 cdnf 및 manf 단편, 이를 포함하는 약학적 조성물 및 그 용도
US20100221240A1 (en) Chemically Modified Peptide Analogs
HUP0401612A2 (hu) Cukorbetegség kezelésére alkalmas gyógyszerkészítmények
JP7553115B2 (ja) 糖尿病治療のためのペプチド断片
CN101300269A (zh) 机械生长因子肽及其用途
WO2025017057A1 (en) Peptides for use in the treatment of axonal damage in diabetes
US20140303093A1 (en) Micro-utrophin polypeptides and methods
US20150166629A1 (en) SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT
KR20230054440A (ko) 심근 손상의 치료 또는 예방에 사용하기 위한 펩타이드
JP2025509119A (ja) 頭蓋脳損傷を治療する方法
HK40017988B (en) Peptides for treatment of diabetes
HK40017988A (en) Peptides for treatment of diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant